We use necessary cookies to make our website work. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference setting. For more information about the use of cookies or our use of data, see our Cookies notice or Privacy notice

Cookies settings I agree I refuse

Cookies information

Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:


We use tools, such as Google Analytics, to track web traffic and verify the effectiveness of our site.


Cookies required for essential services and features such as login forms, shopping cart integration and access control. Without them, our website cannot function properly and we cannot provide any services. Deactivation is not available.

These settings will be kept for 24h



Unique mechanism of action of Ir-CPI

Ir-CPI displays an antithrombotic activity through its interaction with upstream blood coagulation factors (FXIa/FXIIa) of the intrinsic pathway.

Bioxodes has also demonstrated that Ir-CPI decreases neutrophil activation and Neutrophil Extracellular Trap (NET) release. Neutrophils and NETs, networks of extracellular fibers primarily constituted of DNA, are key components of the neuroinflammatory and thrombotic processes encountered in patients with intracerebral hemorrhage (ICH).

Due to its outstanding dual mechanism of action on both coagulation factors and neutrophils, Ir-CPI not only prevents thrombo-inflammatory processes but also represents a promising alternative to current anticoagulants as deficiencies in FXII and FXI protect against thrombosis without causing spontaneous hemorrhage.

The thrombo-inflammatory process
Mechanism of action of Ir-CPI

The thrombo-inflammatory process